Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...

Shares of Novavax fell more than 25% in after-hours trading Tuesday, following a dismal fourth quarter earnings report and a warning from the Covid vaccine maker that uncertainty over future funding ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

Novavax (NVAX) officially handed over U.S. marketing rights for its COVID-19 vaccine, Nuvaxovid, to Sanofi. This milestone triggered a $25 million payment to Novavax and highlights progress in their ...

Novavax (NVAX-0.94%) stock is up around 3,500% so far this year. And that's after a significant recent decline. Earlier this month, shares of Novavax were up nearly 4,400% year to date. These ...

Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut its ...

The Food and Drug Administration announced Tuesday it had authorized Novavax's updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and ...